ArticlePharmacology research & perspectives2021
The selectivity of α-adrenoceptor agonists for the human α1A, α1B, and α1D-adrenoceptors.
Article in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- In Vitro Pharmacology of Mitragynine at α-Adrenoceptors.ACS chemical neuroscience · 2025Article
- A Chemically Stable Photocaged Noradrenaline.ACS chemical neuroscience · 2025Article
- Functional characterization of the αFrontiers in pharmacology · 2025Article
- Part 1 - imidazolines and the changing face of nasal decongestants.Frontiers in pharmacology · 2025Review
- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024Review
- Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments.Handbook of experimental pharmacology · 2024Review
- Alpha-2-adrenergic agonists reduce resting energy expenditure in humans during external cooling.Temperature (Austin, Tex.) · 2024Article
- Structural basis of agonist specificity of αNature communications · 2023Article
- Review
- A Narrative Review of Drug Therapy in Adult and Pediatric Cardiac Arrest.Reviews in cardiovascular medicine · 2023Review
- The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.Pharmacology research & perspectives · 2022Article
- Article
- Intrauterine L-NAME Exposure Weakens the Development of Sympathetic Innervation and Induces the Remodeling of Arterial Vessels in Two-Week-Old Rats.International journal of molecular sciences · 2021Article
- The selectivity of α-adrenoceptor agonists for the human α1A, α1B, and α1D-adrenoceptors.Pharmacology research & perspectives · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Highly selective drugs offer a way to minimize side-effects. For agonist ligands, this could be through highly selective affinity or highly selective efficacy, but this requires careful measurements of intrinsic efficacy. The α1-adrenoceptors are important clinical targets, and α1-agonists are used to manage hypotension, sedation, attention deficit hypersensitivity disorder (ADHD), and nasal decongestion. With 100 years of drug development, there are many structurally different compounds with which to study agonist selectivity. This study examined 62 α-agonists at the three human α1-adrenoceptor (α1A, α1B, and α1D) stably expressed in CHO cells. Affinity was measured using whole-cell
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.